Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
BMC Public Health ; 12: 666, 2012 Aug 16.
Article in English | MEDLINE | ID: mdl-22898005

ABSTRACT

BACKGROUND: Short sleep duration has been reported to associate with increased insulin resistance. However, no studies have investigated whether such association exists in vegetarians. The aim of this study was to investigate the association between sleep duration and insulin resistance in Taiwanese vegetarians. METHODS: A total of 1290 individuals were recruited from a regional hospital in south Taiwan during their regular routine physical examination. Only individuals who described themselves as Buddhist vegetarians were included in the study. Demographic information and clinical characteristics were collected and multiple logistic regression analysis was used to evaluate the association between sleep duration and insulin resistance. RESULTS: A total of 433 vegetarians were included in the study. Results from univariate logistic regression indicated that insulin resistance was significantly associated with male sex, greater waist circumference, higher triglyceride levels, lower high-density lipoprotein cholesterol levels, higher plasma creatinine levels, higher alanine transaminase levels, greater energy expenditure, and sleep duration of more than 8 hours per night. Multiple logistic regression revealed that insulin resistance was significantly and independently associated with sleep duration of more than 8 hours per night (odd ratios = 2.27, 95% confidence interval = 1.24, 4.11) after adjusting for waist circumference and levels of alanine transaminase. CONCLUSIONS: Sleep duration of more than 8 hours per night is an independent risk factor associated with increased insulin resistance in vegetarians.


Subject(s)
Diet, Vegetarian , Insulin Resistance/physiology , Sleep/physiology , Adult , Aged , Buddhism , Female , Humans , Logistic Models , Male , Middle Aged , Surveys and Questionnaires , Taiwan , Time Factors
2.
Cardiovasc Diabetol ; 10: 93, 2011 Oct 17.
Article in English | MEDLINE | ID: mdl-22004541

ABSTRACT

BACKGROUND: The triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) has been advocated as a simple clinical indicator of insulin resistance. Thresholds of TG/HDL-C appeared to depend on ethnicity. However, no studies have specifically compared the accuracy of TG/HDL-C with and without other clinical and demographic factors in predicting insulin resistance in Taiwanese adults. The aim of the present investigation was to use TG/HDL-C and other clinical available factors to predict insulin resistance in Taiwanese adults. METHODS: A total of 812 subjects were recruited from at the time of their general health examination at the Buddhist Dalin Tzu Chi General Hospital, Taiwan. Demographic information and clinical characteristics were obtained. Insulin resistance was defined by the homeostasis model assessment for insulin resistance (HOMA-IR). Simple and multiple logistic regression analyses were used to obtain probabilities of insulin resistance (HOMA-IR > 2) using TG/HDL-C with (Model 2) and without (Model 1) other clinical variables. A receiver operating characteristic (ROC) analysis was conducted to evaluate the ability of the two models to correctly discriminate between subjects of low and elevated HOMA-IR. RESULTS: Female sex, greater waist circumferences, and higher ALT levels were significantly associated with the risk of elevated HOMA-IR in addition to TG/HDL-C in the multiple logistic regression (Model 2). The area under the ROC curve (AUC) of Model 2 was 0.71 [95% CI = 0.67-0.75] and was significantly higher (P = 0.007) than the AUC 0.66 [95% CI = 0.62-0.71] of Model 1. CONCLUSIONS: The diagnostic accuracy of insulin resistance, defined by HOMA-IR, using TG/HDL-C can be significantly enhanced by including three additional clinically available factors - sex, waist circumferences, and ALT levels.


Subject(s)
Cholesterol, HDL/blood , Insulin Resistance/physiology , Triglycerides/blood , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Surveys and Questionnaires , Taiwan/epidemiology , Young Adult
3.
Bioconjug Chem ; 20(4): 774-9, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19323524

ABSTRACT

To improve the self-assembly efficiency of nanoparticles with DNA, we synthesized lysine-based poly(urethane-co-ester) PMMD (6) and polyester PDMA (8) bearing ester linkages in the backbone and tertiary amines in the side chain. Both poly(urethane-co-ester) PMMD (6) and polyester PDMA (8), readily self-assembled with plasmid DNA (pCMV-beta-gal) in HEPES buffer, were characterized by dynamic light scattering and zeta-potential. The results reveal that PMMD (6) and PDMA (8) were able to self-assemble particles with DNA and yield complexes with positive charges of 80-115 nm and 170-180 nm in size at mass ratios (W/W) of 2/1 and 20/1, respectively. The degradation studies indicate that the half-life of PMMD (6) in the HEPES buffer was 20 h at pH 7.4. Titration studies were performed to determine the buffering capacities of the polymers. In addition, the COS-7 cell viabilities in the presence of PMMD/DNA, PDMA/DNA, and PEI/DNA were studied. The results indicate that PMMD (6) is an attractive cationic poly(urethane-co-ester) for gene delivery and an interesting candidate for further study.


Subject(s)
DNA/chemistry , Lysine/chemistry , Nanoparticles/chemistry , Polyurethanes/chemical synthesis , Acrylamides/chemistry , Amines/chemistry , Animals , COS Cells , Cell Survival/drug effects , Chlorocebus aethiops , Drug Design , Ethanol/chemistry , Hydrolysis , Particle Size , Polyurethanes/chemistry , Polyurethanes/toxicity
4.
Clin Exp Pharmacol Physiol ; 35(11): 1301-8, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18671724

ABSTRACT

1. Norsolorinic acid, isolated from Aspergillus nidulans, has been shown to have antiproliferative activity in T24 human bladder cancer cells by arresting the cell cycle at the G(0)/G(1) phase and inducing apoptosis. The aim of the present study was to investigate the antiproliferative activity of norsolorinic acid in T24 human bladder cancer cells. 2. The effects of norsolorinic acid (1, 5, 10 and 20 micromol/L) on the proliferation of T24 cells and on the distribution of cells within different phases of the cell cycle were investigated indirectly using an XTT assay and a flow cytometer, respectively. Factors affecting the cell cycle and apoptosis, including p53, p21, Fas receptor, Fas ligand (FasL) and caspase 8 activity, were examined using ELISA. 3. The results showed that norsolorinic acid inhibited proliferation of T24 cells in a dose-dependent manner, with an IC(50) of 10.5 micromol/L. The effect involved the induction of cell cycle arrest at the G(0)/G(1) phase and apoptosis. 4. These results demonstrate that G(0)/G(1) phase arrest is due to increased expression of p21 in cells treated with norsolorinic acid (10 and 20 micromol/L) for 24 h. Moreover, enhanced Fas and membrane-bound Fas ligand (mFasL) may be responsible for the apoptotic effect of norsolorinic acid. Thus, the present study reports, for the first time, that induction of p21 and the Fas/mFas ligand apoptotic system may participate in the antiproliferative action of norsolorinic acid in T24 human bladder cancer cells.


Subject(s)
Anthraquinones/pharmacology , Apoptosis/drug effects , Cell Proliferation/drug effects , Fas Ligand Protein/metabolism , G1 Phase/drug effects , Resting Phase, Cell Cycle/drug effects , Urinary Bladder Neoplasms/prevention & control , fas Receptor/physiology , Anthraquinones/therapeutic use , Apoptosis/physiology , Cell Line, Tumor , Cell Membrane/metabolism , Cell Membrane/physiology , Fas Ligand Protein/physiology , G1 Phase/physiology , Growth Inhibitors/pharmacology , Growth Inhibitors/therapeutic use , Humans , Membrane Proteins/metabolism , Membrane Proteins/physiology , Protein Binding/drug effects , Protein Binding/physiology , Resting Phase, Cell Cycle/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , Urinary Bladder Neoplasms/pathology , fas Receptor/metabolism
5.
Basic Clin Pharmacol Toxicol ; 102(6): 491-7, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18346044

ABSTRACT

Norsolorinic acid, isolated from the Aspergillus nidulans, was investigated for its antiproliferative activity in human breast adenocarcinoma MCF-7 cells. To identity the anticancer mechanism of norsolorinic acid, we assayed its effect on apoptosis, cell cycle distribution, and levels of p53, p21/WAF1, Fas/APO-1 receptor and Fas ligand. The results showed that norsolorinic acid induced apoptosis of MCF-7 cells without mediation of p53 and p21/WAF1. We suggest that Fas/Fas ligand apoptotic system is the main pathway of norsolorinic acid-mediated apoptosis of MCF-7 cells. Our study reports here for the first time that the activity of the Fas/Fas ligand apoptotic system may participate in the antiproliferative activity of norsolorinic acid in MCF-7 cells.


Subject(s)
Adenocarcinoma/drug therapy , Anthraquinones/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Aspergillus/chemistry , Breast Neoplasms/drug therapy , Fas Ligand Protein/metabolism , fas Receptor/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Anthraquinones/isolation & purification , Antineoplastic Agents, Phytogenic/isolation & purification , Apoptosis/drug effects , Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , Female , Humans , Plant Extracts
6.
Cancer Lett ; 259(1): 82-98, 2008 Jan 18.
Article in English | MEDLINE | ID: mdl-18023967

ABSTRACT

This study is the first to investigate the anticancer effect of plumbagin in human melanoma A375.S2 cells. Plumbagin exhibited effective cell growth inhibition by inducing cancer cells to undergo S-G2/M phase arrest and apoptosis. Further investigation revealed that plumbagin's inhibition of cell growth was also evident in a nude mice model. Blockade of cell cycle was associated with increased levels of p21, and reduced amounts of cyclin B1, cyclin A, Cdc2, and Cdc25C. Plumbagin also enhanced the levels of inactivated phosphorylated Cdc2 and Cdc25C. Plumbagin triggered the mitochondrial apoptotic pathway indicated by a change in Bax/Bcl-2 ratios, resulting in caspase-9 activation. We also found the generation of ROS is a critical mediator in plumbagin-induced cell growth inhibition. Plumbagin increased the activation of apoptosis signal-regulating kinase 1, JNK and extracellular signal-regulated kinase 1/2 (ERK1/2), but not p38. In addition, antioxidants vitamin C and catalase significantly decreased plumbagin-mediated c-Jun N-terminal kinase (JNK) activation and apoptosis. Moreover, blocking ERK and JNK by specific inhibitors suppressed plumbagin-triggered mitochondrial apoptotic pathway. Taken together, these results imply a critical role for ROS and JNK in the plumbagin's anticancer activity.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis/drug effects , Cell Cycle/drug effects , JNK Mitogen-Activated Protein Kinases/metabolism , Melanoma/drug therapy , Naphthoquinones/pharmacology , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , Animals , Antineoplastic Agents, Phytogenic/therapeutic use , Apoptosis Regulatory Proteins/metabolism , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Enzyme Activation , Glutathione/metabolism , Humans , Inhibitory Concentration 50 , MAP Kinase Kinase Kinase 5/metabolism , Male , Melanoma/enzymology , Melanoma/metabolism , Melanoma/pathology , Mice , Mice, Inbred BALB C , Mice, Nude , Mitochondria/drug effects , Mitochondria/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Naphthoquinones/therapeutic use , Neoplastic Stem Cells/drug effects , Phosphorylation , Time Factors , Tumor Stem Cell Assay , Xenograft Model Antitumor Assays
7.
Basic Clin Pharmacol Toxicol ; 101(4): 254-61, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17845507

ABSTRACT

Chalcones (1,3-diphenyl-2-propenone) are cancer preventive food components found in a human diet rich in fruits and vegetables. In this study, we first report the chemopreventive effect of chalcone in two human bladder cancer cell lines: T24 and HT-1376. The results show that chalcone inhibits the proliferation of T24 and HT-1376 cells by inducing apoptosis and blocking cell cycle progression in the G2/M phase. Western blot assay showed that chalcone significantly increases the expression of p21 and p27 proteins, and decreases the levels of cyclin B1, cyclin A and Cdc2, thereby contributing to cell cycle arrest. In addition, chalcone increased the expression of Bax and Bak, but decreased the levels of Bcl-2 and Bcl-X(L) and subsequently triggered mitochondrial apoptotic pathway (release of cytochrome c and activation of caspase-9 and caspase-3). Our study suggests that the induction of mitochondrial pathway and inhibition of the nuclear factor kappa B survival system may play important roles in the antiproliferative activity of chalcone in T24 and HT-1376 cells.


Subject(s)
Anticarcinogenic Agents/pharmacology , Apoptosis , Chalcone/pharmacology , Mitochondria/physiology , NF-kappa B/antagonists & inhibitors , Blotting, Western , CDC2 Protein Kinase/metabolism , Caspases/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cyclin A/metabolism , Cyclin B/metabolism , Cyclin B1 , Humans , NF-kappa B/physiology , Signal Transduction , Urinary Bladder Neoplasms , bcl-2 Homologous Antagonist-Killer Protein/metabolism , bcl-2-Associated X Protein/metabolism
8.
Biochem Pharmacol ; 73(4): 504-14, 2007 Feb 15.
Article in English | MEDLINE | ID: mdl-17113042

ABSTRACT

Myricetin (3,3',4',5,5',7-hexahydroxyflavone), a flavonoid compound, is present in vegetables and fruits. By means of alkaline phosphatase (ALP) activity, osteocalcin, and type I collagen enzyme-linked immunosorbent assay (ELISA), we have shown that myricetin exhibits a significant induction of differentiation in MG-63 and hFOB human osteoblasts. Alkaline phosphatase and osteocalcin are phenotypic markers for early-stage differentiated osteoblasts and terminally differentiated osteoblasts, respectively. Our results indicate that myricetin stimulates osteoblast differentiation at various stages, from maturation to terminally differentiated osteoblasts. Induction of differentiation by myricetin is associated with increased bone morphogenetic protein-2 (BMP-2) production. The BMP-2 antagonist noggin blocked myricetin-mediated ALP activity and osteocalcin secretion enhancement, indicating that BMP-2 production is required in myricetin-mediated osteoblast maturation and differentiation. Induction of differentiation by myricetin is associated with increased activation of SMAD1/5/8 and p38 mitogen-activated protein kinases. Cotreatment of p38 inhibitor SB203580 inhibited myricetin-mediated ALP upregulation and osteocalcin production. In conclusion, myricetin increased BMP-2 synthesis, and subsequently activated SMAD1/5/8 and p38 MAPK, and this effect may contribute to its action on the induction of osteoblast maturation and differentiation, followed by an increase of bone mass.


Subject(s)
Bone Morphogenetic Proteins/metabolism , Cell Differentiation/drug effects , Flavonoids/pharmacology , Osteoblasts/drug effects , Transforming Growth Factor beta/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Alkaline Phosphatase/metabolism , Autoantigens/metabolism , Bone Morphogenetic Protein 2 , Carrier Proteins/pharmacology , Cell Line , Cell Line, Tumor , Collagen Type I/metabolism , Cycloheximide/pharmacology , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay , Humans , Imidazoles/pharmacology , Osteoblasts/cytology , Osteoblasts/metabolism , Osteocalcin/metabolism , Protein Synthesis Inhibitors/pharmacology , Pyridines/pharmacology , Ribonucleoproteins, Small Nuclear/metabolism , Signal Transduction/drug effects , Smad5 Protein/metabolism , Smad8 Protein/metabolism , Time Factors , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , snRNP Core Proteins
9.
Eur J Pharmacol ; 551(1-3): 1-9, 2006 Dec 03.
Article in English | MEDLINE | ID: mdl-17026990

ABSTRACT

Piceatannol (3,3',4,5'-tetrahydroxy-trans-stilbene) is a polyphenol present in grapes and wine. By means of alkaline phosphatase activity and osteocalcin enzyme-linked immunosorbent assay (ELISA), we have shown that piceatannol exhibits a significant induction of differentiation in immortalized fetal osteoblasts (hFOB), and osteosarcoma cells (MG-63). Alkaline phosphatase and osteocalcin are phenotypic markers for early-stage differentiated osteoblasts and terminally differentiated osteoblasts, respectively, our results indicate that piceatannol stimulate osteoblast differentiation at various stages (from maturation to terminally differentiated osteoblasts). Induction of differentiation by piceatannol was associated with increased bone morphogenetic protein-2 (BMP-2) production. Addition of purified BMP-2 protein did not increase the upregulation of alkaline phosphatase activity and osteocalcin secretion by piceatannol, whereas the BMP-2 antagonist noggin blocked piceatannol and BMP-2-mediated alkaline phosphatase activity, and osteocalcin secretion enhancement, indicating that BMP-2 production is required in piceatannol-mediated osteoblast maturation and differentiation. In conclusion, piceatannol increased BMP-2 synthesis, and this effect may contribute to its action on the induction of osteoblasts maturation and differentiation, followed by an increase of bone mass. Decreases in new bone formation, followed by estrogen deficiency or various pathologic factors, may contribute to the mechanisms involved in postmenopausal osteoporosis.


Subject(s)
Bone Density Conservation Agents/pharmacology , Bone Morphogenetic Proteins/biosynthesis , Cell Differentiation/drug effects , Osteoblasts/drug effects , Osteogenesis/drug effects , Stilbenes/pharmacology , Transforming Growth Factor beta/biosynthesis , Alkaline Phosphatase/metabolism , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/antagonists & inhibitors , Calcification, Physiologic/drug effects , Carrier Proteins/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Collagen Type I/metabolism , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Humans , Osteoblasts/cytology , Osteoblasts/metabolism , Osteocalcin/metabolism , Protein Biosynthesis/drug effects , RNA, Messenger/metabolism , Time Factors , Transcription, Genetic/drug effects , Transforming Growth Factor beta/antagonists & inhibitors , Up-Regulation/drug effects
10.
Int J Pharm ; 327(1-2): 117-25, 2006 Dec 11.
Article in English | MEDLINE | ID: mdl-16963207

ABSTRACT

The aim of this study is to investigate how the presence of liquid crystal, cholesteryl oleyl carbonate, embedded into polymers (PMMA, Eb270, PU) affects the biocompatibility of composite membranes with human blood. The effects of different surface textures of composite membranes on platelet adhesion and platelet activation were evaluated as well. The adhesion and geometric deformation of platelets were demonstrated by SEM. The quantitative assay of platelet activation was determined by measuring the production of P-Selectin, and by measurement of the blood clotting index when PRP blood was incubated with pure polymer films and composite membranes. Moreover, the hemolysis studies on the damage to red blood cells were performed to gain information on the hemocompatibility of these biomaterials. The results showed that inclusion of cholesteryl oleyl carbonate (COC) embedded in composite membranes, improves their biocompatibility with respect to a substantial reduction of platelet adhesion and the controlled decrease of platelet activation. As the COC content of composite membranes was increased, the value of the blood clotting index increased and the production of P-Selectin decreased. The results also showed that the presence of COC resulted in a decrease of hemolysis ratios. Comparing among three different composite membranes, the best biocompatibility is achieved when PU/COC> or ==Eb270/COC>PMMA/COC. The in vitro studies performed in this work suggest that it may be reasonable to use liquid crystal COC as a mean of surface modification to improve the blood compatibility of biopolymers.


Subject(s)
Acrylic Resins/toxicity , Liquid Crystals/toxicity , Membranes, Artificial , Polymethyl Methacrylate/toxicity , Polyurethanes/toxicity , Acrylic Resins/chemistry , Adsorption , Blood Coagulation/drug effects , Carbonates/chemistry , Carbonates/toxicity , Cells, Cultured , Erythrocytes/drug effects , Erythrocytes/pathology , Hemolysis/drug effects , Humans , Liquid Crystals/chemistry , Materials Testing , Platelet Activation/drug effects , Platelet Adhesiveness/drug effects , Polymethyl Methacrylate/chemistry , Polyurethanes/chemistry
11.
Int Immunopharmacol ; 6(7): 1167-75, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16714221

ABSTRACT

The survival of osteoblast cells is one of the determinants of the development of osteoporosis in patients with inflamed synovium, such as in rheumatoid arthritis (RA). By means of alkaline phosphatase (ALP) activity and osteocalcin ELISA assay, we have shown that fraxetin exhibits a significant induction of differentiation in the human osteoblast-like cell line MG-63. In addition, we also assessed whether fraxetin affects inflammatory cytokine-mediated apoptosis in osteoblast cells. TNF-alpha or IL-1beta enhance apoptotic DNA fragmentation in anti-Fas IgM-treated MG-63 cells by increasing Fas receptor expression. However, TNF-alpha or IL-1beta treatment alone does not induce apoptosis. Treatment of MG-63 cells with fraxetin not only inhibited anti-Fas IgM-induced apoptosis, but also blocked the synergetic effect of anti-Fas IgM with TNF-alpha or IL-1beta on cell death. The apoptotic inhibition of fraxetin is associated with inhibition of TNF-alpha and IL-1beta-mediated Fas expression and enhancement of FLIP expression, resulting in a decrease of caspase-8 and caspase-3 activation. These results indicate a potential use of fraxetin in preventing osteoporosis by inhibiting inflammatory cytokine-mediated apoptosis in osteoblast cells.


Subject(s)
Apoptosis/drug effects , Cell Differentiation/drug effects , Coumarins/pharmacology , Osteoblasts/drug effects , fas Receptor/metabolism , Alkaline Phosphatase/metabolism , CASP8 and FADD-Like Apoptosis Regulating Protein , Caspase 3 , Caspase 8 , Caspases/metabolism , Cell Line , Humans , Immunoglobulin M , Interleukin-1/pharmacology , Intracellular Signaling Peptides and Proteins/metabolism , Osteoblasts/cytology , Osteoblasts/metabolism , Osteocalcin/immunology , Tumor Necrosis Factor-alpha/pharmacology
12.
Biol Pharm Bull ; 29(1): 119-24, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16394523

ABSTRACT

Fraxetin (7,8-dihydroxy-6-methoxy coumarin), a coumarin derivative, was investigated for its effects on differentiation of osteoblasts. By means of alkaline phosphatase (ALP) activity and osteocalcin ELISA assay, we have shown that fraxetin exhibits a significant induction of differentiation in two human osteoblast-like cell lines, MG-63 and hFOB. Alkaline phosphatase and osteocalcin are phenotypic markers for early-stage differentiated osteoblasts and terminally differentiated osteoblasts, respectively. Our results indicated that fraxetin stimulated osteoblast differentiation at various stages (from osteoprogenitors to terminally differentiated osteoblasts). Induction of differentiation by fraxetin was associated with increased bone morphogenetic protein-2 (BMP-2) and BMP-4 productions. Addition of purified BMP-2 and BMP-4 proteins did not increase the upregulation of ALP activity and osteocalcin secretion by fraxetin, whereas the BMPs antagonist noggin blocked both fraxetin and BMP-2 and BMP-4 mediated ALP activity and osteocalcin secretion enhancement, indicating that BMP-2 and BMP-4 productions are required in fraxetin-mediated osteoblast maturation and differentiation. These findings are novel and may be important in the treatment and prevention of osteoporosis.


Subject(s)
Antioxidants/pharmacology , Bone Morphogenetic Proteins/metabolism , Coumarins/pharmacology , Osteoblasts/drug effects , Transforming Growth Factor beta/metabolism , Alkaline Phosphatase/metabolism , Bone Morphogenetic Protein 2 , Bone Morphogenetic Protein 4 , Cell Differentiation/drug effects , Cell Line , Cell Proliferation/drug effects , Humans , Osteocalcin/metabolism
13.
J Pharmacol Exp Ther ; 314(3): 1290-9, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15956019

ABSTRACT

The survival of osteoblast cells is one of the determinants of the development of osteoporosis in patients. Osthole (7-methoxy-8-isopentenoxycoumarin) is a coumarin derivative present in many medicinal plants. By means of alkaline phosphatase (ALP) activity, osteocalcin, osteopontin, and type I collagen, enzyme-linked immunosorbent assay, we have shown that osthole exhibits a significant induction of differentiation in two human osteoblast-like cell lines, MG-63 and hFOB. Induction of differentiation by osthole was associated with increased bone morphogenetic protein (BMP)-2 production and the activations of SMAD1/5/8 and p38 and extracellular signal-regulated kinase (ERK) 1/2 kinases. Addition of purified BMP-2 protein did not increase the up-regulation of ALP activity and osteocalcin by osthole, whereas the BMP-2 antagonist noggin blocked both osthole and BMP-2-mediated ALP activity enhancement, indicating that BMP-2 production is required in osthole-mediated osteoblast maturation. Pretreatment of osteoblast cells with noggin abrogated p38 activation but only partially decreased ERK1/2 activation, suggesting that BMP-2 signaling is required in p38 activation and is partially involved in ERK1/2 activation in osthole-treated osteoblast cells. Cotreatment of p38 inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole] or p38 small interfering RNA (siRNA) expression inhibited osthole-mediated activation of ALP but only slightly affected osteocalcin production. In contrast, the production of osteocalcin induced by osthole was inhibited by the mitogen-activated protein kinase kinase inhibitor PD98059 (2'-amino-3'-methoxyflavone) or by expression of an ERK2 siRNA. These data suggest that BMP-2/p38 pathway links to the early phase, whereas ERK1/2 pathway is associated with the later phase in osthole-mediated differentiation of osteoblast cells. In this study, we demonstrate that osthole is a promising agent for treating osteoporosis.


Subject(s)
Bone Morphogenetic Proteins/physiology , Cell Differentiation/drug effects , Coumarins/pharmacology , MAP Kinase Signaling System/physiology , Mitogen-Activated Protein Kinase 1/physiology , Mitogen-Activated Protein Kinase 3/physiology , Osteoblasts/drug effects , Transforming Growth Factor beta/physiology , p38 Mitogen-Activated Protein Kinases/physiology , Bone Morphogenetic Protein 2 , Cell Proliferation/drug effects , Cells, Cultured , DNA-Binding Proteins/physiology , Humans , Osteoblasts/cytology , Osteoporosis/drug therapy , Osteoporosis/etiology , RNA, Small Interfering/pharmacology , Smad Proteins , Smad1 Protein , Trans-Activators/physiology
14.
Anticancer Drugs ; 16(4): 409-15, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15746577

ABSTRACT

Casuarinin, a hydrolyzable tannin isolated from the bark of Terminalia arjuna Linn. (Combretaceae), inhibits human non-small cell lung cancer A549 cells by blocking cell cycle progression in the G0/G1 phase and inducing apoptosis. Enzyme-linked immunosorbent assay showed that the G0/G1 phase arrest is due to p53-dependent induction of p21/WAF1. An enhancement in Fas/APO-1 and the two forms of Fas ligand (FasL), membrane-bound FasL and soluble FasL, might be responsible for the apoptotic effect induced by casuarinin. Our study reports here for the first time that the induction of p53 and the activity of the Fas/FasL apoptotic system may participate in the antiproliferative activity of casuarinin in A549 cells.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis/drug effects , Carcinoma, Non-Small-Cell Lung/drug therapy , G1 Phase/drug effects , Hydrolyzable Tannins/pharmacology , Resting Phase, Cell Cycle/drug effects , Terminalia , Cell Cycle Proteins/metabolism , Cell Proliferation , Cyclin-Dependent Kinase Inhibitor p21 , Dose-Response Relationship, Drug , Fas Ligand Protein , Humans , Lung Neoplasms/drug therapy , Membrane Glycoproteins/metabolism , Plant Bark/chemistry , Plant Extracts/pharmacology , Receptors, Tumor Necrosis Factor/metabolism , Tumor Cells, Cultured , Tumor Suppressor Protein p53/metabolism , fas Receptor
15.
Planta Med ; 71(3): 237-43, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15770544

ABSTRACT

Casuarinin, a hydrolyzable tannin isolated from the bark of Terminalia arjuna L. (Combretaceae), was investigated for its antiproliferative activity in human breast adenocarcinoma MCF-7 cells. The results showed that casuarinin inhibited the proliferation of MCF-7 by blocking cell cycle progression in the G0/G1 phase and inducing apoptosis. An enzyme-linked immunosorbent assay showed that casuarinin increased the expression of p21/WAF1 concomitantly as the MCF-7 cells underwent G0/G1 arrest. An enhancement in Fas/APO-1 and its two forms of ligands, membrane-bound Fas ligand (mFasL) and soluble Fas ligand (sFasL), might be responsible for the apoptotic effect induced by casuarinin. Our study reports here for the first time that the induction of p21/WAF1 and the activity of Fas/Fas ligand apoptotic system may participate in the antiproliferative activity of casuarinin in MCF-7 cells.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis/drug effects , Cell Cycle/drug effects , Hydrolyzable Tannins/pharmacology , Phytotherapy , Terminalia , Adenocarcinoma/prevention & control , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/therapeutic use , Breast Neoplasms/prevention & control , Cell Line, Tumor/drug effects , Dose-Response Relationship, Drug , Female , Humans , Hydrolyzable Tannins/administration & dosage , Hydrolyzable Tannins/therapeutic use , Plant Bark , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Plant Extracts/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...